Rethinking brain health

We are on a mission to change the way the world thinks about brain health.

Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.

The Challenge

Our novel technology assesses brain health based on changes in the cellular structure.

Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.

This gives us the potential to revolutionise how people think about brain health and disease management.

Our solution

Supporting more efficient drug development and personalised patient care.

Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.

Our Science

Our products


  • Measures you can trust
  • Get more from your MRI
  • Run targeted, more efficient clinical trials
  • Efficient use of technology across multiple conditions

Our products


  • Better patient care
  • Improving certainty in diagnosis
  • Differential diagnosis for Dementia
  • Accurately tracking decline
  • Proactive brain health

Clinical Information

Latest news

OBD Guest Speaker series Dr Catherine Mummery
19 May 2022

A huge thanks to Dr Catherine Mummery for taking the OBD team through an extensive tour of the novel approaches in #dementia We found the discussions and the Q&A interactions insighful. The future looks incredibly promising and taking into account the developments in gene therapy is to be noted and kept a very close eye on.

CDM selected as secondary outcome measure in Phase 2 AD Trial.
News Release
30 March 2022

Cortical Disarray Measurement (CDM) has been appointed as a secondary outcome measure for a Randomized, Placebo, Controlled, Double-Blind Study of XPro™ in Patients with Mild Alzheimer’s Disease with Biomarkers of Inflammation. The trial sponsor is INmune Bio, a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that harness the patient’s innate immune system to fight disease.

OBD Guest Speaker series Professor Malu Tansey
24 March 2022

It was our pleasure to host and listen to Professor Malú Gámez Tansey at the Oxford Brain Diagnostics guest speaker series. Prof Tansey is currently Director of the Center for Translational Research in Neurodegenerative Disease (CTRND) and the first endowed Norman and Susan Fixel Chair in Neuroscience and Neurology at University of Florida. A very insightful dicussion into the contrbution neuroinflammation has in parkinson's disease. In addtion, research was shared on the role of the gut brain axis in PD.

OBD Guest Speaker series Professor Craig Ritchie
01 March 2022

Professor Craig Ritchie is currently Professor of Psychiatry of Ageing at the University of Edinburgh. He is also Director at Brain Health Scotland, a non for profit organisation on a mission to inspire and empower you to protect your brain health and reduce your risk of diseases that lead to dementia. A wonderful discussion was had on Brain Health issues, early diagnosis and tracking patient outcomes with smart biomarkers.